These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 34278936)
41. [Pharmacokinetic issues on cancer pharmacotherapy]. Tanigawara Y Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690 [TBL] [Abstract][Full Text] [Related]
42. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Menz BD; Stocker SL; Verougstraete N; Kocic D; Galettis P; Stove CP; Reuter SE Br J Clin Pharmacol; 2021 Feb; 87(2):227-236. PubMed ID: 32430968 [TBL] [Abstract][Full Text] [Related]
43. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Chatelut E; Hendrikx JJMA; Martin J; Ciccolini J; Moes DJAR Pharmacol Res Perspect; 2021 Apr; 9(2):e00757. PubMed ID: 33745217 [TBL] [Abstract][Full Text] [Related]
45. Optimizing dosing of antibiotics in critically ill patients. Parker SL; Sime FB; Roberts JA Curr Opin Infect Dis; 2015 Dec; 28(6):497-504. PubMed ID: 26382000 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic drug monitoring in cancer chemotherapy. Bach DM; Straseski JA; Clarke W Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218 [TBL] [Abstract][Full Text] [Related]
47. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299 [TBL] [Abstract][Full Text] [Related]
48. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine. Gaspar VP; Ibrahim S; Zahedi RP; Borchers CH J Mass Spectrom; 2021 Nov; 56(11):e4788. PubMed ID: 34738286 [TBL] [Abstract][Full Text] [Related]
49. [Determination of blood levels for oral anticancer drugs]. van Erp NP; van der Graaf WT Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023 [TBL] [Abstract][Full Text] [Related]
50. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Rovithi M; Gerritse SL; Honeywell RJ; Ten Tije AJ; Ruijter R; Peters GJ; Voortman J; Labots M; Verheul HMW J Clin Oncol; 2019 Feb; 37(5):411-418. PubMed ID: 30586316 [TBL] [Abstract][Full Text] [Related]
57. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Baselga J; Mita AC; Schöffski P; Dumez H; Rojo F; Tabernero J; DiLea C; Mietlowski W; Low C; Huang J; Dugan M; Parker K; Walk E; van Oosterom A; Martinelli E; Takimoto CH Clin Cancer Res; 2012 Nov; 18(22):6364-72. PubMed ID: 23014528 [TBL] [Abstract][Full Text] [Related]
58. [Personalized medicine for oral molecular-targeted anticancer drugs]. Miura M Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517 [TBL] [Abstract][Full Text] [Related]
59. Precision Dosing of Targeted Therapies Is Ready for Prime Time. Groenland SL; Verheijen RB; Joerger M; Mathijssen RHJ; Sparreboom A; Beijnen JH; Beumer JH; Steeghs N; Huitema ADR Clin Cancer Res; 2021 Dec; 27(24):6644-6652. PubMed ID: 34548319 [TBL] [Abstract][Full Text] [Related]
60. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring. Knezevic CE; Clarke W Ther Drug Monit; 2020 Feb; 42(1):6-19. PubMed ID: 31568180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]